Average Co-Inventor Count = 11.57
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Signal Pharmaceuticals, Inc. (20 from 169 patents)
2. Bristol-myers Squibb Compnay (1 from 3,684 patents)
3. Celgene Corporation (1 from 549 patents)
4. Juno Therapeutics Gmbh (66 patents)
21 patents:
1. 12404239 - Modulators of BCL6 as ligand directed degraders
2. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
3. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
4. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
5. 9783505 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
6. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
7. 9557338 - Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
8. 9556126 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
9. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors
10. 9155736 - Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
11. 9156798 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
12. 9079900 - Methods of synthesis and purification of heteroaryl compounds
13. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
14. 8569494 - Methods of synthesis and purification of heteroaryl compounds
15. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway